Loading clinical trials...

Prolactin and FGF21 in Gestational Diabetes Mellitus | Clinical Trials | Clareo Health

UNKNOWN

Prolactin and FGF21 in Gestational Diabetes Mellitus

NCT05528393•Shen Qu

Summary

Prolactin (PRL) and PRL receptor (PRLR) signaling has been validated to play an important role in the modulation of glucolipid metabolism. However, the role of serum PRL levels in gestational diabetes mellitus (GDM) remains unclear. The investigators aimed to explore the possible influence of serum PRL within or without normal range on the development of GDM.

Eligibility

Age

18 - 45 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•aged 18 to 45 years
•completed a 75-g oral glucose tolerance test (OGTT)
•females with pregnancy

Exclusion Criteria

•severe liver and renal dysfunction, preexisting heart disease, malignancy, or endocrine diseases such as pituitary adenoma and hypogonadism
•mental illness
•genetic disease
•current or previous treatment that might affect PRL and insulin secretion
•diabetes before pregnancy
•loss to follow-up, or withdrawal from the study
•unable to understand and comply with the study protocol.

Locations (1)

Shanghai Tenth People's Hospital

Shanghai, China

Key Dates

Start Date

January 1, 2017

Primary Completion Date

September 1, 2022

Completion Date

December 1, 2022

Last Updated

September 6, 2022

Enrollment

200

ESTIMATED participants

Conditions

Gestational Diabetes Mellitus in PregnancyHyperprolactinemia Pregnancy

Interventions

Blood sampling

DIAGNOSTIC_TEST

Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes

NCT06948825

Weight LossGestational Diabetes Mellitus in Pregnancy+1 more

View study

RECRUITINGNA

Intrapartum Glucose Control and Risk of Neonatal Hypoglycemia

NCT06643351

Gestational Diabetes Mellitus in PregnancyPregestational Diabetes Mellitus+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 6, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Prolactin and FGF21 in Gestational Diabetes Mellitus

Inclusion Criteria

Exclusion Criteria

Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes

Intrapartum Glucose Control and Risk of Neonatal Hypoglycemia

MIRACLE of LIFE Study

Self-Administered 2-Hour Oral Glucose Tolerance Test

Effects of Rhythm-Based Music on Pregnancies With Gestational Diabetes

D-chiro Inositol in Prevention of Gestational Diabetes Mellitus in China